Caribou Biosciences, Inc. (CRBU)
0.4123
-0.03
(-7.22%)
USD |
NASDAQ |
Nov 05, 16:00
0.4355
+0.02
(+5.63%)
After-Hours: 07:06
Caribou Biosciences SG&A Expense (TTM) : 33.74M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 33.74M |
| March 31, 2026 | 36.24M |
| December 31, 2025 | 37.91M |
| September 30, 2025 | 39.82M |
| June 30, 2025 | 40.47M |
| March 31, 2025 | 41.55M |
| December 31, 2024 | 46.46M |
| September 30, 2024 | 45.69M |
| June 30, 2024 | 45.56M |
| March 31, 2024 | 44.20M |
| December 31, 2023 | 38.46M |
| September 30, 2023 | 37.27M |
| June 30, 2023 | 37.41M |
| Date | Value |
|---|---|
| March 31, 2023 | 37.34M |
| December 31, 2022 | 38.02M |
| September 30, 2022 | 37.34M |
| June 30, 2022 | 34.25M |
| March 31, 2022 | 29.32M |
| December 31, 2021 | 24.32M |
| September 30, 2021 | 16.47M |
| June 30, 2021 | 12.96M |
| March 31, 2021 | 11.00M |
| December 31, 2020 | 9.889M |
| September 30, 2020 | 9.889M |
| June 30, 2020 | 6.642M |
| March 31, 2020 | 3.489M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Anavex Life Sciences Corp. | 5.935M |
| Intellia Therapeutics, Inc. | 105.74M |
| Vir Biotechnology, Inc. | 77.15M |
| Vaxcyte, Inc. | 100.22M |
| Foghorn Therapeutics, Inc. | 26.38M |